Bill

S 5012

Prohibits health insurers from requiring prior authorization for anti-retroviral medication used to treat and prevent HIV infection

2025 Regular Session Introduced by Pete Harckham and 1 co-sponsor

Prohibits health insurers from requiring prior authorization for anti-retroviral meds (ART) to treat HIV and for PrEP, speeding access and reducing treatment delays.

REFERRED TO HEALTH

WeVote Research Nonpartisan

Bill Summary · S 5012

Summary of S 5012

Overview

S 5012 is a bill introduced on February 18, 2025, that would prohibit health insurers from requiring prior authorization for anti-retroviral medications used to treat and prevent HIV infection. The bill is currently in the Health committee stage, having been referred to the Health committee on Feb. 18, 2025.

Purpose and intent

The primary aim is to remove the need for prior authorization (PA) for anti-retroviral therapies (ART) used to treat HIV and for preventive ART (commonly known as PrEP).
By eliminating PA requirements, the bill seeks to streamline access to HIV treatment and prevention medications, reducing potential delays in care.

Key provisions (as indicated by the bill’s title)

Prohibition on PA: Health insurers would not be allowed to require prior authorization for anti-retroviral medications used to treat HIV infection.
Coverage focus: The provision targets medications used for treatment (ART) and prevention (PrEP) of HIV infection.

Note: The full text of the bill would specify any definitions, scope (which insurers are covered, such as private, public, or state-regulated plans), exemptions, and enforcement mechanisms. The summary here is based on the bill’s title and status.

Who would be affected

Patients: Individuals prescribed ART or PrEP would face fewer administrative barriers to obtaining their medications.
Providers and pharmacies: Prescribers and pharmacies would experience less PA-related workflow and potential delays.
Insurers: Health insurers subject to the bill would need to adjust PA processes (or remove them entirely for the relevant medications).

Legislative status and timeline

Introduced: February 18, 2025.
Legislative actions: Referred to Health on February 18, 2025 (listed twice in the actions).
Current position: Awaiting action in the Health committee.
Sponsors: Primary sponsor Pete Harckham; cosponsor Lea Webb.
Related bills from prior sessions: S 8981 and S 5374 (indicating prior related proposals).

Additional context and considerations

Administrative impact: Likely reduction in administrative steps for ART/PrEP access; insurers may experience changes in utilization management practices for these medications.
Fiscal impact: Not specified in available information; potential cost implications for insurers versus public health benefits from improved access.
Next steps: If approved by the Health committee, the bill would advance through the chamber, potentially undergo amendments, and require votes before moving to further chambers or becoming law.